Moat Biotechnology key facts
as of Oct 2026- Developer of oral vaccines designed to accelerate the treatment of infectious diseases.
- Moat Biotechnology is valued at approximately $56.5M as of Oct 2026 (last reported valuation).
- It has raised $8.2M across 1 recorded rounds; the latest was Debt ($1.5M) in Jun 2022.
- Notable investors include Cortado Ventures, Boyd Street Ventures.
- Moat Biotechnology has filed 3 Form Ds with the SEC since 2022, most recently Feb 2023 ($102K sold to 2 investors).
- Status: Privately Held (backing).
Moat Biotechnology's last reported valuation, Dec 2023. Nothing priced has surfaced since.
- ·Watch Moat Biotechnology: the Monday email on marks, rounds and moves
Moat Biotechnology funding rounds
1 roundsWho backs Moat Biotechnology
2Moat Biotechnology valuation
Moat Biotechnology's last reported valuation was $56.5 million in Dec 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Moat Biotechnology raised?
Moat Biotechnology has raised $8.2 million in total; 1 of its rounds is on record. The largest on record was a $1.5 million debt round in Jun 2022.
Moat Biotechnology has filed 3 Form Ds with the SEC since 2022, most recently in Feb 2023 ($101,640 sold to 2 investors).
Moat Biotechnology investors
2 investors are on record for Moat Biotechnology, including Cortado Ventures and Boyd Street Ventures. The debt round in Jun 2022 drew 2 investors.
About Moat Biotechnology
Developer of oral vaccines designed to accelerate the treatment of infectious diseases. The company holds an complete patent license for the novel second-generation single-cycle adenovirus vaccine platform to develop intranasal and oral vaccines that can elicit and boost both mucosal and systemic immunity for the treatment of viruses and infectious diseases, enabling patients with significantly advanced treatment over existing and traditional vaccines.
- Sector
- Healthcare
- HQ
- Oklahoma City, OK, United States
- Founded
- 2022
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.